帕瑞昔布钠对腹腔镜胆囊切除术后的镇痛作用及安全性研究

目的 探讨帕瑞昔布钠对腹腔镜胆囊切除术后的镇痛效果和安全性.方法 将90例行腹腔镜胆囊切除术患者按随机数字表法分为帕瑞昔布钠组、氟比洛芬酯组和对照组,每组30例,均于术前30min给予不同药物.观察并比较三组视觉模拟评分(VAS)、镇痛满意度、凝血功能和血小板聚集试验的最大聚集率(MAR)及术后不良反应等.结果 帕瑞昔布钠组、氟比洛芬酯组术后不同时间点VAS和精神症状发生率均明显低于对照组(P＜0.05),术后24 h镇痛满意率分别为93.3%(28/30)和90.0%(27/30),均明显高于对照组[20.0%(6/30)](P＜0.05);三组给药前后凝血功能和MAR比较差异无统计学意义(P＞0.05).结论 帕瑞昔布钠对腹腔镜胆囊切除术后的镇痛效果好,不良反应发生率低,值得临床推广应用.

Analgesic efficacy and safety of parecoxib-sodium in patients undergoing laparoscopic cholecystectomy

Objective To investigate the analgesic efficacy and safety of parecoxib-sodium in patients undergoing laparoscopic cholecystectomy. Methods Ninety patients received laparoscopic cholecystectomy were divided into parecoxib-sodium group,flurbiprofen group and control group by random digits table, 30 cases in each group, all patients received the drug by vein 30 minutes before surgery. The postoperative pain intensity (VAS score), satisfaction of patients, changes of blood coagulation function and maximum agglutination rate (MAR) of platelet agglutination test before and after treatment and the incidence of postoperative adverse reaction were observed and compared. Results Pestoperative VAS scores and psychiatric symptoms at different time in parecoxib-sodium group and flurbiprofen group were significantly lower than those in control group (P ＜ 0.05), analgesic satisfaction rate were 93.3% (28/30) in parecoxibsodium group and 90.0% (27/30) in flurbiprofen group, which were significantly higher than that in control group [20.0%(6/30)] (P＜0.05). There were no significant difference in blood coagulation function and MAR before and after treatment among three groups (P ＞ 0.05). Conclusion Parecoxib-sodium displays significant analgesic effects and low rate of adverse events for the patients undergoing laparoscopic cholecystectomy, it is worthy of clinical application.